NSE's DRHP: The Verdict, Scored Against Its Own Bull Case

The Method

Most DRHP coverage describes. This is a verdict. Six criteria, each scored against NSE's own filed evidence, then weighed against the strongest counterargument for owning the stock. If the bull case survives contact with the filing, the verdict says so. Here, it mostly doesn't.

What NSE's DRHP Actually Says

National Stock Exchange of India Limited filed its Draft Red Herring Prospectus with SEBI on June 17, 2026. Unlike most IPOs, this one carries no fresh issue. It is a 100% offer-for-sale of up to 14,89,05,525 equity shares — about 6% of NSE's 247.5 crore total shares. The company raises zero rupees. Every rupee goes to selling shareholders.

Criterion 1: Governance — FAIL

Evidence: NSE's 2019 SEBI order on the colocation matter directed disgorgement of Rs 624.89 crore plus 12% annual interest since April 2014, and a six-month market access ban. SAT set aside the disgorgement in 2023 but ordered Rs 100 crore paid to the Investor Education and Protection Fund. SEBI appealed both SAT rulings to the Supreme Court — both appeals remain pending. NSE offered to settle the colocation and Dark Fibre matters for Rs 1,387.39 crore in June 2025, then raised that offer to Rs 1,491.21 crore in March 2026, three months before filing this DRHP. It has booked a Rs 1,391.21 crore provision against FY26 profit.

Bull case: SAT has ruled in NSE's favor twice — disgorgement set aside, AO penalties set aside. The regulatory cloud is thinning, not thickening.

Why it doesn't hold: SAT's rulings were procedural — lack-of-due-diligence findings, not exonerations of the underlying conduct. SEBI's Supreme Court appeals keep the ceiling open. And the direction of travel on NSE's own settlement offer is upward, not downward. A company confident the case is closing does not raise its own settlement bid by over Rs 100 crore right before an IPO. Verdict: fail.

Criterion 2: Earnings Quality — WEAKENING

Evidence: FY26 PAT was Rs 10,302 crore, down 15.5% from FY25's Rs 12,188 crore. Revenue from operations fell 3.1%, to Rs 16,601 crore.

Bull case: The Rs 1,391 crore settlement provision is a one-off. Add it back and PAT normalizes to roughly Rs 11,693 crore — a much smaller decline, arguably just noise.

Why it doesn't hold: The provision sits in "other expenses," separate from revenue. Revenue fell on its own, before any provision is added back. Even the fully normalized PAT (Rs 11,693 crore) is still below FY25's Rs 12,188 crore. This is not one bad line item distorting an otherwise clean year — the underlying business also softened. Verdict: weakening, not explained away by the one-off.

Criterion 3: Growth Durability — FAIL

Evidence: PAT CAGR FY24→FY26 was 11.4%, but that average is inflated by FY25's 46.7% spike. The most recent single year fell 15.5%.

Bull case: One weak year in an otherwise structurally growing market — India's derivatives volumes have grown for a decade, and this is reversion, not decline.

Why it doesn't hold: NSE's own DRHP discloses that the STT hikes on options and futures — effective April 2026 — fall entirely in FY27, a year that hasn't been reported yet. Options alone are 60.22% of FY26 revenue from operations. The single biggest headwind to NSE's largest revenue line has not yet shown up in any number we've seen. The bull case is calling the bottom before the next hit lands. Verdict: fail — the hardest part of the growth test is still ahead, not behind.

Criterion 4: Moat Durability — WEAKENING

Evidence: NSE's own filing discloses NCL's settlement market share fell from 94.24% to 88.42% in cash market, and from 95.67% to 91.04% in equity derivatives, in one year. SEBI's May 2025 single-weekly-expiry rule handed BSE Thursday and NSE Tuesday — a regulatory equalizer of a structural advantage NSE held for years.

Bull case: NSE still holds 74.71% of equity options by premium turnover — the metric that actually drives its fee revenue. That's dominance, not decline.

Why it doesn't hold: 74.71% is still a majority, but it's the number NSE chose to disclose without a prior-year comparison — worth noticing what wasn't shown. Meanwhile the metrics NSE did show YoY (clearing share) both fell, sharply, in a single year. A moat that's eroding in every metric with a year-over-year comparison, while touting a metric with none, is not evidence the moat is intact. Verdict: weakening.

Criterion 5: Relative Positioning vs. BSE — FAIL

Evidence: BSE's most recently declared quarterly results (Q4 FY26, Jan–Mar 2026, exchange-filed) show revenue of Rs 1,564 crore, up 84.7% year-on-year from Rs 847 crore, and net profit of Rs 795 crore, up 60.9% from Rs 494 crore, with operating margin expanding to 67% from 57%. NSE, in the same industry and the same year, posted declining revenue and declining profit.

Bull case: BSE is growing off a far smaller base — 85% growth on Rs 847 crore is easier than equivalent growth on NSE's Rs 16,601 crore. NSE remains roughly 10x larger in absolute terms; scale still favors NSE.

Why it doesn't hold: Scale should defend a moat, not excuse a shrinking one. BSE isn't just growing in aggregate — it's gaining specifically in the derivatives clearing segment where NSE's own filing shows share eroding. A monopoly with contracting share, next to a listed peer with expanding share and accelerating growth, is the same signal as the other criteria, not a mitigating one. Verdict: fail — the trend lines are moving in opposite directions.

Criterion 6: Valuation vs. Fundamentals — FAIL

Evidence: NSE's unlisted shares have traded around Rs 2,000–2,100 across pre-IPO dealer platforms in the past two weeks — not a SEBI-verified price; NSE is not yet listed, and its DRHP leaves the price band blank, as is standard. At 247.5 crore shares (the DRHP's own share count), that implies a market cap of roughly Rs 4.95–5.2 lakh crore.

We ran a reverse two-stage DCF: FY26 PAT of Rs 10,302 crore as the base, an 11% discount rate, 5% terminal growth, ten years of explicit high growth. To justify a Rs 4.95 lakh crore valuation, NSE needs to compound profit at roughly 18.4% a year, every year, for a decade.

Bull case: NSE is a structural monopoly with 33% ROE and 67% operating margins — multiples like this are earned by businesses this good.

Why it doesn't hold: NSE's own actual 2-year PAT CAGR is 11.4%, and that's the generous number. Run the same DCF at that historical rate and fair value comes out to roughly Rs 2.91 lakh crore — 41% below where the grey market prices it today. Run it flat, at 0% growth, and fair value is roughly Rs 1.24 lakh crore — a quarter of today's implied price. Being a good business doesn't close an 18.4%-vs-11.4% gap. Being a great business might close half of it. Verdict: fail — the valuation requires a growth rate the company's own filed history doesn't support.

The Verdict

Four fails, two weakenings, zero clean passes. The bull case was given its strongest form on every count — procedural SAT wins, one-off provision add-back, structural monopoly economics, secular market growth, scale advantage — and it still doesn't close the gap on any of the six.

This OFS is not VCs exiting a startup. It's SBI, four PSU insurers, Bank of Baroda, Indian Bank, Morgan Stanley, Temasek and Canada's pension fund, selling a legacy stake in a monopoly — at a price that assumes the monopoly keeps compounding at a rate its own DRHP no longer supports.

Source: National Stock Exchange of India Ltd. Draft Red Herring Prospectus, filed with SEBI June 17, 2026 (sebi.gov.in). BSE quarterly figures from BSE Ltd.'s exchange-filed results. NSE unlisted share price from pre-IPO dealer platforms, not SEBI-verified — flagged as such. This is not investment advice.